TG Therapeutics (NASDAQ:TGTX) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a strong sell rating to a hold rating in a research note published on Monday morning,Zacks.com reports.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. cut their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of TG Therapeutics in a research note on Wednesday, May 27th. Wall Street Zen lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $52.50.

TG Therapeutics Trading Down 2.1%

NASDAQ:TGTX opened at $36.64 on Monday. The firm’s fifty day moving average is $36.35 and its 200-day moving average is $32.37. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. TG Therapeutics has a 52 week low of $25.28 and a 52 week high of $44.65. The firm has a market cap of $5.61 billion, a P/E ratio of 12.81 and a beta of 1.68.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The firm had revenue of $204.92 million during the quarter, compared to the consensus estimate of $200.33 million. During the same period in the prior year, the company posted $0.03 earnings per share. The company’s revenue for the quarter was up 69.5% compared to the same quarter last year. Equities analysts expect that TG Therapeutics will post 1.31 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Danske Bank A S bought a new position in shares of TG Therapeutics in the third quarter valued at $25,000. Optiver Holding B.V. lifted its stake in shares of TG Therapeutics by 3,485.7% in the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 732 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of TG Therapeutics by 117.1% in the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 486 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 365 shares in the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in shares of TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 560 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.